LV-DDC-GCH1-BMSCs

**LV-DDC-GCH1-BMSCs** are an experimental, lentivirally engineered rat bone marrow-derived mesenchymal stem-cell product developed for **Parkinson's disease**. The cells are transduced with a lentiviral construct expressing human **DDC** and **GCH1**, two enzymes involved in dopamine biosynthesis, then selected with blasticidin to establish a stable cell line. In a 6-hydroxydopamine-lesioned rat model, intracerebral transplantation increased dopamine-associated activity and reduced apomorphine-induced rotational behavior, although the dual-gene cell product was less active than the separate triple-enzyme DA-BMSC product that also expressed tyrosine hydroxylase. It is a preclinical research cell therapy and has no reported clinical development or marketed use. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11992172/))

Other names

LV-DDC-GCH1 BMSCsLV-DDC-GCH-1 BMSCsLV-DDC-GCH 1 BMSCsLV-DDC-GCH1 bone marrow-derived mesenchymal stem cellsLV-DDC-GCH-1 bone marrow-derived mesenchymal stem cellsLV-DDC-GCH 1 bone marrow-derived mesenchymal stem cellsLV-DDC-GCH1-BMSCsLV-DDC-GCH-1-BMSCsLV-DDC-GCH 1-BMSCs